MIGLUSTAT (MIG loo stat) helps to keep normal blood levels of an enzyme needed to breakdown fat in the body. It is used to treat type 1 Gaucher disease.
Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford
GlycoSciences and marketed by Actelion and is used primarily to treat type I ...
Lancet Neurol. 2007 Sep;6(9):765-72. Miglustat for treatment of Niemann-Pick C
disease: a randomised controlled study. Patterson MC(1), Vecchio D, Prady H, ...
Official product website with information for consumers and health professionals.
Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme
glucosylceramide synthase, which is a glucosyl transferase enzyme responsible
for the first ...
Jun 13, 2005 ... Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme
glucosylceramide synthase, an essential enzyme for the synthesis of ...
Easy to read patient leaflet for miglustat. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Zavesca® (miglustat) is currently the only approved oral treatment for patients
with mild to moderate type 1 Gaucher disease for whom enzyme replacement ...
Each capsule contains 100 mg miglustat. For the full list of excipients, see section
6.1. 3. PHARMACEUTICAL FORM. Hard capsule. White capsules with “OGT ...
is supplied in hard gelatin capsules each containing 100 mg miglustat for oral
administration. Each ZAVESCA. ®. 100 mg capsule also contains sodium starch.